Micol Jean-Baptiste, Duployez Nicolas, Boissel Nicolas, Petit Arnaud, Geffroy Sandrine, Nibourel Olivier, Lacombe Catherine, Lapillonne Helene, Etancelin Pascaline, Figeac Martin, Renneville Aline, Castaigne Sylvie, Leverger Guy, Ifrah Norbert, Dombret Hervé, Preudhomme Claude, Abdel-Wahab Omar, Jourdan Eric
Hematology Department, INSERM Unité Mixte de Recherche 1009, Gustave Roussy Cancer Campus Grand Paris, Villejuif, Paris-Sud University, Orsay, France; Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY;
Laboratory of Hematology and Tumor Bank, INSERM U837 Team 3, Cancer Research Institute of Lille, Centre Hospitalier Régional Universitaire of Lille, University Lille Nord de France, Lille, France;
Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27.
Acute myeloid leukemia (AML) with t(8;21) (q22;q22) is considered to have favorable risk; however, nearly half of t(8;21) patients are not cured, and recent studies have highlighted remarkable genetic heterogeneity in this subset of AML. Here we identify somatic mutations in additional sex combs-like 2 (ASXL2) in 22.7% (25/110) of patients with t(8;21), but not in patients with inv(16)/t(16;16) (0/60) or RUNX1-mutated AML (0/26). ASXL2 mutations were similarly frequent in adults and children t(8;21) and were mutually exclusive with ASXL1 mutations. Although overall survival was similar between ASXL1 and ASXL2 mutant t(8;21) AML patients and their wild-type counterparts, patients with ASXL1 or ASXL2 mutations had a cumulative incidence of relapse of 54.6% and 36.0%, respectively, compared with 25% in ASXL1/2 wild-type counterparts (P = .226). These results identify a high-frequency mutation in t(8;21) AML and identify the need for future studies to investigate the clinical and biological relevance of ASXL2 mutations in this unique subset of AML.
伴有t(8;21)(q22;q22)的急性髓系白血病(AML)被认为具有良好的风险;然而,近一半的t(8;21)患者未被治愈,并且最近的研究强调了该AML亚组中显著的基因异质性。在此,我们在22.7%(25/110)的t(8;21)患者中鉴定出额外性梳样蛋白2(ASXL2)的体细胞突变,但在inv(16)/t(16;16)患者(0/60)或RUNX1突变的AML患者(0/26)中未发现。ASXL2突变在成人和儿童t(8;21)患者中同样常见,并且与ASXL1突变相互排斥。虽然ASXL1和ASXL2突变的t(8;21)AML患者及其野生型对应者的总生存率相似,但ASXL1或ASXL2突变的患者复发累积发生率分别为54.6%和36.0%,而ASXL1/2野生型对应者为25%(P = 0.226)。这些结果确定了t(8;21)AML中的高频突变,并确定了未来研究调查ASXL2突变在这一独特AML亚组中的临床和生物学相关性的必要性。